Genotyping of Cytomegalovirus From Patients in Israel

NCT ID: NCT00228202

Last Updated: 2006-08-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The researchers select 100 cytomegalovirus (CMV) DNA samples from patients diagnosed with CMV infection. Patients include bone marrow transplant patients, pregnant women and newborns. The researchers determine viral load by real-time polymerase chain reaction (PCR). They amplify CMV-gB sequences by PCR and type by sequencing and restriction fragment length polymorphism (RFLP). The researchers obtain clinical data from patients' records. They examine association between patients' clinical status and CMV-gB genotype and viral load.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims at finding association between CMV viral load and viral glycoprotein B genotype and the clinical status of patients suffering from CMV infection. Bone marrow transplant patients are at increased risk of developing severe CMV disease and are routinely followed for viral load. Fetuses are also at high risk for developing severe malformations and neurological defects following maternal primary infection during pregnancy. Therefore amniotic fluid from women diagnosed with CMV infection is examined for CMV presence. Newborns having congenital defects are tested for CMV excretion.

There is not yet any confirmed marker for assessment of the potential severity of the viral infection and for prognosis. Therefore we shall attempt to find association between the viral load and genotype and the clinical status.

CMV DNA samples prepared at the Central Virology Laboratory from clinical specimens obtained from patients for diagnostic purposes will be coded and then subjected to viral load analysis using real-time PCR. The gB genotype will be determined by either of two methods described in the literature: (a) PCR and RFLP (b) PCR and sequencing.

Relevant clinical data will be retrieved from the patients clinical records and saved as coded information to match the samples. Bone marrow transplant patients will be followed for prolonged periods covering repeated viral reactivation events. Clinical records from mothers and newborns will be matched when present. Otherwise maternal and newborn samples will be kept as is.

Statistical analysis will be performed to try and find association between the clinical status of patients, the viral load and the viral genotype.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cytomegalovirus Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

cytomegalovirus CMV pregnancy amniotic fluid bone marrow transplantation viral load glycoprotein B genotyping PCR real-time PCR CMV disease Congenital CMV infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

NATURAL_HISTORY

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* CMV DNA sample from a transplant patient with CMV disease.
* CMV DNA from amniotic fluid of women with CMV infection
* CMV DNA from urine of newborns with congenital defects compatible with CMV.
Minimum Eligible Age

0 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sheba Medical Center

OTHER_GOV

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Naty Keller, MD/PhD

Role: STUDY_DIRECTOR

Sheba Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Central Virology Laboratory, Chaim Sheba Medical Center Tel-Hashomer

Ramat Gan, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ella Mendelson, PhD

Role: CONTACT

Phone: 972-3-530-2421

Email: [email protected]

Naty Keller, MD/PhD

Role: CONTACT

Phone: 972-3-530-2304

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ella Mendelson, PhD

Role: primary

Zehava Grossman, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Sara Orzi MSc thesis

Identifier Type: -

Identifier Source: secondary_id

SHEBA-05-3867-NK-CTIL

Identifier Type: -

Identifier Source: org_study_id